发明名称 |
Methods for concomitant treatment of theophylline and febuxostat |
摘要 |
The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline. |
申请公布号 |
US9107912(B2) |
申请公布日期 |
2015.08.18 |
申请号 |
US201113227828 |
申请日期 |
2011.09.08 |
申请人 |
Takeda Pharmaceuticals U.S.A., Inc. |
发明人 |
Gunawardhana Lhanoo;Tsai Max;Naik Himanshu |
分类号 |
A61K31/522;A61K31/426;A61K31/415;A61K45/06 |
主分类号 |
A61K31/522 |
代理机构 |
Michael Best & Friedrich LLP |
代理人 |
Mueller Lisa V.;Michael Best & Friedrich LLP |
主权项 |
1. A method of treating hyperuricemia in a patient in need of treatment thereof, the method comprising the steps of:
administering to a patient suffering from hyperuricemia and at least one second disease state, a therapeutically effective amount of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein the subject is also receiving concomitant administration of theophylline to treat the at least one second disease state, and further wherein (i) the administration of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, to the patient does not result in theophylline toxicity to the patient; and (ii) administration of the theophylline is in an amount ranging from about 90% to about 110% of a manufacturer's recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor. |
地址 |
Deerfield IL US |